Caris Life Sciences (CAI) EBITDA (2024 - 2026)

Caris Life Sciences' EBITDA history runs 3 years deep, the most recent figure standing at -$553000.0 for Q1 2026.

• In Q1 2026, EBITDA rose 99.46% year-over-year to -$553000.0; the TTM figure through Mar 2026 stood at $34.6 million (up 112.66% YoY), while the FY2025 annual figure was -$67.4 million, up 76.1% from the prior year.
• EBITDA was -$553000.0 for Q1 2026 at Caris Life Sciences, down from $82.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $82.1 million in Q4 2025 to a low of -$102.5 million in Q1 2025.
• Historically, EBITDA has averaged -$29.9 million across 3 years, with a median of -$51.5 million in 2024.
• Biggest YoY gain for EBITDA was 322.36% in 2025; the steepest drop was 7.98% in 2025.
• A 3-year view of EBITDA shows it stood at -$36.9 million in 2024, then jumped by 322.36% to $82.1 million in 2025, then plunged by 100.67% to -$553000.0 in 2026.
• The last three EBITDA figures came in at -$553000.0 (Q1 2026), $82.1 million (Q4 2025), and $24.4 million (Q3 2025), per Business Quant data.